Rare disease Eiger focuses on rare metabolic diseases with a lead candidate avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, signaling opportunities to partner with specialty clinics, patient advocacy groups, and niche distributors serving endocrinology and metabolic centers.

Bankruptcy asset sales Recent bankruptcy proceedings led to asset divestitures including lonafarnib and avexitide transactions, creating potential acquisition or licensing opportunities for buyers, licensors, or portfolio consolidation partners seeking late-stage or near-market assets.

Commercial stage As a commercial-stage biopharma with FDA Breakthrough Therapy designation for avexitide, there is momentum to pursue co-promotion, distribution collaborations, or market-access partnerships to accelerate adoption in PBH and HI treatment settings.

Funding stability With funding around mid-range and modest revenue, there is room for strategic partnerships, co-development of pipeline assets, or contract manufacturing and services arrangements to optimize cash flow and scale operations.

Technical ecosystem Eiger’s tech stack and digital presence indicate readiness for partner integrations, including cloud-based data collaboration, compliant reporting, and digital marketing collaborations; opportunities exist for CRO/CMO, clinical data services, and market-access tech collaborations.